We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
Read MoreHide Full Article
Key Takeaways
Liquidia's Yutrepia generated $300.3 million in first-half 2026 sales after a strong launch.
United Therapeutics' Tyvaso DPI directly overlaps with Yutrepia as an inhaled dry-powder therapy.
Insmed's TPIP could add pressure as it advances phase III trials in PAH and PH-ILD.
Liquidia Corporation (LQDA - Free Report) is gaining strong commercial momentum with Yutrepia, but intensifying competition in the pulmonary arterial hypertension (PAH) market could make it increasingly challenging for the drug to sustain its growth trajectory.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology is designed to deliver the drug deep into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
The FDA approved Yutrepia in May 2025 for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and the drug was launched in June 2025. Since then, Yutrepia has quickly emerged as Liquidia’s key growth driver, generating approximately $300.3 million in sales in the first half of 2026. The company has recorded about 5,900 unique prescriptions since launch, with more than 5,000 patients initiating treatment and nearly 1,100 physicians prescribing the therapy.
However, Yutrepia operates in a highly competitive PAH market, where established therapies and emerging pipeline candidates could constrain its ability to gain market share. PAH treatment includes multiple drug classes and combination regimens, giving physicians several options across endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, activin signaling inhibitors and prostacyclin-based therapies.
UTHR Has an Established Inhaled Treprostinil Franchise
United Therapeutics (UTHR - Free Report) represents one of Yutrepia’s most direct competitors. Its Tyvaso (treprostinil) inhalation solution has been approved for PAH since 2009 and for PH-ILD since 2021, giving the company a long-established position in the inhaled treprostinil market.
UTHR also markets Tyvaso DPI, a dry-powder formulation of treprostinil that was approved in 2022 for PAH and PH-ILD. The product directly overlaps with Yutrepia’s positioning as an inhaled dry-powder therapy, making UTHR a particularly important competitor as Liquidia seeks to expand adoption.
UTHR is also broadening its pulmonary hypertension franchise. In September 2026, the FDA accepted the company’s supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF). The review is expected to be completed in late April 2027.
The FDA also accepted UTHR’s new drug application for ralinepag to treat PAH in August 2026, setting a target action date of June 24, 2027. Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the FDA.
INSM’s Pipeline Could Increase Future Pressure
Insmed (INSM - Free Report) represents another potential competitive threat through its investigational therapies, particularly TPIP.
TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, progressive pulmonary fibrosis (PPF) and IPF.
Insmed is currently enrolling patients in the PALM-ILD and PALM-PAH phase III trials evaluating TPIP in PH-ILD and PAH, respectively. The company recently reported positive 12-month data from an ongoing open-label extension study in PAH.
Insmed is advancing a phase II program for INS1148, initially targeting PPF and IPF, with the potential to expand into other pulmonary diseases.
Yutrepia Needs to Stand Out
Liquidia is looking to expand Yutrepia into additional indications, including hypertension associated with chronic obstructive pulmonary disease, IPF, PPF and systemic-sclerosis-associated Raynaud’s phenomenon.
Thus, while Yutrepia’s strong launch, proprietary PRINT technology and growing physician adoption provide a solid foundation, sustaining growth will depend on Liquidia’s ability to differentiate Yutrepia and defend its market position against both established products and emerging therapies. With UTHR strengthening its inhaled treprostinil franchise and INSM advancing TPIP across several overlapping indications, competition is likely to remain a key factor shaping Yutrepia’s long-term growth potential.
LQDA’s Share Price Performance, Valuation, Estimates and Zacks Rank
Shares of LQDA have lost 9.1% in the past three months against the industry’s growth of 5.3%.
Image Source: Zacks Investment Research
Going by the price/sales ratio, LQDA shares currently trade at 6.08X forward sales, higher than the industry’s average of 1.91X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south to $2.57 from $3.02, and that for 2027 EPS has declined to $4.38 from $5.31 in the past 60 days.
View the Zacks #1 Rank List
Image: Bigstock
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
Key Takeaways
Liquidia Corporation (LQDA - Free Report) is gaining strong commercial momentum with Yutrepia, but intensifying competition in the pulmonary arterial hypertension (PAH) market could make it increasingly challenging for the drug to sustain its growth trajectory.
Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia’s proprietary PRINT technology. The technology is designed to deliver the drug deep into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies.
The FDA approved Yutrepia in May 2025 for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and the drug was launched in June 2025. Since then, Yutrepia has quickly emerged as Liquidia’s key growth driver, generating approximately $300.3 million in sales in the first half of 2026. The company has recorded about 5,900 unique prescriptions since launch, with more than 5,000 patients initiating treatment and nearly 1,100 physicians prescribing the therapy.
However, Yutrepia operates in a highly competitive PAH market, where established therapies and emerging pipeline candidates could constrain its ability to gain market share. PAH treatment includes multiple drug classes and combination regimens, giving physicians several options across endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, activin signaling inhibitors and prostacyclin-based therapies.
UTHR Has an Established Inhaled Treprostinil Franchise
United Therapeutics (UTHR - Free Report) represents one of Yutrepia’s most direct competitors. Its Tyvaso (treprostinil) inhalation solution has been approved for PAH since 2009 and for PH-ILD since 2021, giving the company a long-established position in the inhaled treprostinil market.
UTHR also markets Tyvaso DPI, a dry-powder formulation of treprostinil that was approved in 2022 for PAH and PH-ILD. The product directly overlaps with Yutrepia’s positioning as an inhaled dry-powder therapy, making UTHR a particularly important competitor as Liquidia seeks to expand adoption.
UTHR is also broadening its pulmonary hypertension franchise. In September 2026, the FDA accepted the company’s supplemental new drug application for nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF). The review is expected to be completed in late April 2027.
The FDA also accepted UTHR’s new drug application for ralinepag to treat PAH in August 2026, setting a target action date of June 24, 2027. Ralinepag has the potential to redefine the PAH treatment landscape as the first and only once-daily oral prostacyclin, if approved by the FDA.
INSM’s Pipeline Could Increase Future Pressure
Insmed (INSM - Free Report) represents another potential competitive threat through its investigational therapies, particularly TPIP.
TPIP is an inhaled dry powder formulation of the treprostinil prodrug treprostinil palmitil, which may offer a differentiated product profile for PH-ILD, PAH, progressive pulmonary fibrosis (PPF) and IPF.
Insmed is currently enrolling patients in the PALM-ILD and PALM-PAH phase III trials evaluating TPIP in PH-ILD and PAH, respectively. The company recently reported positive 12-month data from an ongoing open-label extension study in PAH.
Insmed is advancing a phase II program for INS1148, initially targeting PPF and IPF, with the potential to expand into other pulmonary diseases.
Yutrepia Needs to Stand Out
Liquidia is looking to expand Yutrepia into additional indications, including hypertension associated with chronic obstructive pulmonary disease, IPF, PPF and systemic-sclerosis-associated Raynaud’s phenomenon.
Thus, while Yutrepia’s strong launch, proprietary PRINT technology and growing physician adoption provide a solid foundation, sustaining growth will depend on Liquidia’s ability to differentiate Yutrepia and defend its market position against both established products and emerging therapies. With UTHR strengthening its inhaled treprostinil franchise and INSM advancing TPIP across several overlapping indications, competition is likely to remain a key factor shaping Yutrepia’s long-term growth potential.
LQDA’s Share Price Performance, Valuation, Estimates and Zacks Rank
Shares of LQDA have lost 9.1% in the past three months against the industry’s growth of 5.3%.
Image Source: Zacks Investment Research
Going by the price/sales ratio, LQDA shares currently trade at 6.08X forward sales, higher than the industry’s average of 1.91X but lower than its mean of 14.68X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved south to $2.57 from $3.02, and that for 2027 EPS has declined to $4.38 from $5.31 in the past 60 days.
Image Source: Zacks Investment Research
LQDA currently has a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.